THE BENEFITS AND RISKS OF A TRICOMPONENT GEL CONTAINING
PIROXICAM, LIDOCAINE AND CYCLOBENZAPRINE, IN MUSCULOSKELETAL INJURIES IN ATHLETES
ALIN NICOLAE POPESCU *, EMIL COTENESCU, BEATRICE COSTANDACHE, BOGDAN GHERGHICEANU, MARIUS LICA TODOSI
Romanian Rugby Federation Medical Centre, 20 Mărăști Boulevard, District 1, Bucharest, Romania
*corresponding author: garda1108@yahoo.com
DownloadDownload Full Article

Abstract:
Sport-related injuries produces local inflammation, pain, oedema and local sensitivity. The pain is accompanied by impaired
mobility and functionality and, in severe traumas, by disability. The present non-interventional study assessed the efficacy
and safety of a topical combination of a NSAID (piroxicam 5 mg/g) with two sodium channel blockers anaesthetics
(lidocaine 20 mg/g, cyclobenzaprine hydrochloride 5 mg/g) as a topical tricomponent gel (PLC) versus a topical gel only
with a NSAID (piroxicam 10 mg/g) but in higher concentration, in the management of pain in sport related musculoskeletal
injuries. The study was conducted on 90 rugby players from Romanian National Rugby Lot. The significant effectiveness of
PLC gel was obvious from the first results in day 2: in the PLC gel group, pain on movement decreased by 17.91% and pain
on pressure by 19.6% versus 9.28% and 10.12% respectively in the Piroxicam 1% gel group. Patients in the PLC gel group
reported pain alleviation 15 minutes subsequent to topical application, and the effect lasted for an average of 11 hours. The
effect of Piroxicam 1% gel was reported after an average of 52 minutes, but longer intervals of 80 minutes were also
reported. The effect of Piroxicam 1% gel lasted up to 6 hours. The results from day 7 and then day 14 confirmed the superior
efficacy of PLC gel versus Piroxicam 1% gel previously noticed in the results of the first visit. In day 14 in the PLC group
pain alleviation increased by 70% considering both parameters, while in the Piroxicam 1% gel group it did not go beyond
45%. The analysis of the pain-free patients at the end of the treatment revealed an efficacy of 32% in pain on movement and
57% in pain on pressure in the PLC group and 2.32% in pain on movement and 6.97% in pain on pressure in the Piroxicam
1% gel group.






Top